Biotechnology stocks have performed well of late as companies from across the globe earn more investments. According to a report from Boulder-based data company OnBioVC, biotech companies attracted close to double the amount of investment in the fourth quarter of … Continue reading →

Cardium Therapeutics today announced that it has completed the previously announced sale of 17,857,143 shares of its common stock in a registered direct offering for gross proceeds of approximately $5.0 million, before deducting placement agent’s fees and estimated offering expenses. … Continue reading →

Cardium Therapeutics today announced that it has entered into definitive agreements with three institutional and accredited investors to sell an aggregate of 17,857,143 shares of its common stock in a registered direct offering for gross proceeds of approximately $5.0 million, … Continue reading →

Cardium Therapeutics today reported on new insights and confirmatory preclinical study results on the Generx (Ad5FGF-4) angiogenic therapy product candidate based on the Company’s sponsored research conducted at Emory University.  The findings, which provide further support for the apparent safety … Continue reading →

Biotechnology stocks have been on fire of late. The iShares Biotechnology index is up more than 12 percent over the last month as investors brace for big drug launches, FDA hearings, and greater M&A activity in the coming months. The … Continue reading →

Cardium Therapeutics today reported that it had received notice from NYSE Regulation that the Company is now considered to have regained compliance with the listing requirements of the NYSE Amex LLC (formerly the American Stock Exchange). (Logo:  http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO) In the … Continue reading →

Cardium Therapeutics today announced that it has entered into its first international agreement for the commercialization of Excellagen™ in the South Korean market. Cardium entered into a marketing and distribution agreement with BL&H Co. Ltd., an established pharmaceutical company based … Continue reading →

Cardium Therapeutics today announced that it is scheduled to present at the Biotech Showcase 2012 and the 5th Annual OneMedForum Conference in San Francisco. (Logo: http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO) The 2012 Biotech Showcase is being held at the Parc 55 Wyndham in San … Continue reading →

Cardium Therapeutics Inc. today reported on its exchange listing compliance with NYSE Amex LLC (formerly the American Stock Exchange). The Company reports that its estimated stockholders’ equity is now in excess of the threshold requirements under Section 1003(a)(iii) of the … Continue reading →

Cardium Therapeutics Inc. today announced that it has entered into a cross-strategic investment agreement with SourceOne Global Partners, a leading supplier of exclusive science-based ingredients and proprietary formulas to the nutritional supplement and related functional food & beverage industries. The … Continue reading →